Related Experiment Video

Updated: Aug 5, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Cisplatin gel treatment of unresectable liver cancer

Cathel Kerr

    The Lancet. Oncology
    |April 12, 2003
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
    07:47

    Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

    Published on: December 13, 2015

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Related Experiment Videos

    Last Updated: Aug 5, 2026

    Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
    09:52

    Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

    Published on: January 25, 2015

    Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
    07:47

    Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

    Published on: December 13, 2015

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.

    The Lancet. Oncology·2026

    Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer.

    The Lancet. Oncology·2026

    Cancer and the microbiome: from association to intervention.

    The Lancet. Oncology·2026

    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial.

    The Lancet. Oncology·2026

    Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.

    The Lancet. Oncology·2026

    Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.

    Obesity science & practice·2026

    Successful Breast-Conserving Surgery Following Dose-Modified Neoadjuvant Chemoimmunotherapy in an 86-Year-Old Patient With Locally Advanced Triple-Negative Breast Cancer: A Case Report.

    Clinical case reports·2026

    I need it. Without it, I wouldn't have gone, and I do want to go: patient perspectives on the acceptability and appropriateness of two patient-centered interventions to improve adherence to annual lung cancer screening.

    Frontiers in health services·2026

    Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinoma.

    Oncology reviews·2026

    Development of a risk-stratified follow-up strategy based on early and late recurrence risk factors in locally advanced esophageal squamous cell carcinoma after definitive chemoradiotherapy.

    Frontiers in oncology·2026

    Multimodality therapy for stage IB3 cervical cancer with a delayed diagnosis at 21 weeks of gestation: from neoadjuvant chemotherapy to adjuvant chemoradiotherapy-a case report.

    Frontiers in medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us